Chinese Biotech Firm HJ Science Tumbles in Hong Kong Trading Debut Amid Stiff Competition

Dow Jones

06/23

By Jason Chau

Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry.

Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering.

The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet.

According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged that some of the competing products possess significant competitive strengths and advantages over its own offerings.

Still, overall market sentiment around China's biopharma sector remains strong, supported by breakthroughs in advanced drug development, rapid rollouts of innovative therapies, and a wave of licensing deals with global pharmaceutical giants.

Write to Jason Chau at jason.chau@wsj.com

(END) Dow Jones Newswires

June 23, 2026 01:27 ET (05:27 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2645959000"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645959000\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645959000?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 13:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645959000","market":"nz","top_or_hot":-1,"title":"Chinese Biotech Firm HJ Science Tumbles in Hong Kong Trading Debut Amid Stiff Competition","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Jason Chau \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry. \n</p>\n<p>\n  Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering. \n</p>\n<p>\n  The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet. \n</p>\n<p>\n  According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged that some of the competing products possess significant competitive strengths and advantages over its own offerings. \n</p>\n<p>\n  Still, overall market sentiment around China's biopharma sector remains strong, supported by breakthroughs in advanced drug development, rapid rollouts of innovative therapies, and a wave of licensing deals with global pharmaceutical giants. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Jason Chau at jason.chau@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 01:27 ET (05:27 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Biotech Firm HJ Science Tumbles in Hong Kong Trading Debut Amid Stiff Competition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Biotech Firm HJ Science Tumbles in Hong Kong Trading Debut Amid Stiff Competition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-23 13:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Jason Chau \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry. \n</p>\n<p>\n  Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering. \n</p>\n<p>\n  The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet. \n</p>\n<p>\n  According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged that some of the competing products possess significant competitive strengths and advantages over its own offerings. \n</p>\n<p>\n  Still, overall market sentiment around China's biopharma sector remains strong, supported by breakthroughs in advanced drug development, rapid rollouts of innovative therapies, and a wave of licensing deals with global pharmaceutical giants. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Jason Chau at jason.chau@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 01:27 ET (05:27 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645959000","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645959000","pubTimestamp":1782192420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry.Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering.The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet.According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged tha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","06132":"华健未来-B","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"中国生物技术公司HJ Science在香港首次交易中因激烈竞争而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"06132":0.9},"content_text":"By Jason Chau \n\n\n \n\n\n  Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry. \n\n\n  Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering. \n\n\n  The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet. \n\n\n  According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged that some of the competing products possess significant competitive strengths and advantages over its own offerings. \n\n\n  Still, overall market sentiment around China's biopharma sector remains strong, supported by breakthroughs in advanced drug development, rapid rollouts of innovative therapies, and a wave of licensing deals with global pharmaceutical giants. \n\n\n \n\n\n  Write to Jason Chau at jason.chau@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2026 01:27 ET (05:27 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}